Description
Background: Cergutuzumab amunaleukin (CEA-IL2v) is a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent CEA-specific antibody devoid of Fc-mediated effector functions. It is under investigation for treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Cergutuzumab amunaleukin are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Cergutuzumab amunaleukin present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Cergutuzumab amunaleukin antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Cergutuzumab amunaleukin in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!